Last reviewed · How we verify

Enriched Ringer's lactate solution — Competitive Intelligence Brief

Enriched Ringer's lactate solution (Enriched Ringer's lactate solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Crystalloid intravenous fluid. Area: Critical Care / Fluid Management.

marketed Crystalloid intravenous fluid Critical Care / Fluid Management Small molecule Live · refreshed every 30 min

Target snapshot

Enriched Ringer's lactate solution (Enriched Ringer's lactate solution) — Scientific Institute San Raffaele. Enriched Ringer's lactate solution is an intravenous fluid replacement therapy that restores electrolyte balance and provides hydration to maintain cellular and circulatory homeostasis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Enriched Ringer's lactate solution TARGET Enriched Ringer's lactate solution Scientific Institute San Raffaele marketed Crystalloid intravenous fluid
Plasma-lyte Plasma-lyte Fundación Santa Fe de Bogota marketed Crystalloid intravenous fluid / Electrolyte replacement solution
Lactated Ringer's Solution Lactated Ringer's Solution McGill University Health Centre/Research Institute of the McGill University Health Centre marketed Crystalloid intravenous fluid
Ringer lactato Ringer lactato Federal University of Juiz de Fora marketed Crystalloid intravenous fluid
fluidotherapy with ringer-lactate fluidotherapy with ringer-lactate Medical University of Vienna marketed Crystalloid intravenous fluid
Ringer lactate (RL) Ringer lactate (RL) Fundación Cardioinfantil Instituto de Cardiología marketed Crystalloid intravenous fluid
Ringer-acetat Ringer-acetat Rigshospitalet, Denmark marketed Crystalloid intravenous fluid

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Crystalloid intravenous fluid class)

  1. Fayoum University Hospital · 1 drug in this class
  2. Federal University of Juiz de Fora · 1 drug in this class
  3. Fundación Cardioinfantil Instituto de Cardiología · 1 drug in this class
  4. McGill University Health Centre/Research Institute of the McGill University Health Centre · 1 drug in this class
  5. Medical University of Vienna · 1 drug in this class
  6. Nationwide Children's Hospital · 1 drug in this class
  7. Rigshospitalet, Denmark · 1 drug in this class
  8. Scientific Institute San Raffaele · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Enriched Ringer's lactate solution — Competitive Intelligence Brief. https://druglandscape.com/ci/enriched-ringer-s-lactate-solution. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: